Literature DB >> 11711410

Treatment of chronic hepatitis.

P J Gow1, D Mutimer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11711410      PMCID： PMC1121644          DOI： 10.1136/bmj.323.7322.1164

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  18 in total

1.  Effectiveness of interferon therapy for reducing the incidence of hepatocellular carcinoma among patients with type C chronic hepatitis.

Authors:  A Inoue; H Tsukuma; A Oshima; T Yabuuchi; M Nakao; T Matsunaga; J Kojima; S Tanaka
Journal:  J Epidemiol       Date:  2000-07       Impact factor: 3.211

2.  Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.

Authors:  J P Villeneuve; L D Condreay; B Willems; G Pomier-Layrargues; D Fenyves; M Bilodeau; R Leduc; K Peltekian; F Wong; M Margulies; E J Heathcote
Journal:  Hepatology       Date:  2000-01       Impact factor: 17.425

3.  Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.

Authors:  T Poynard; J McHutchison; G L Davis; R Esteban-Mur; Z Goodman; P Bedossa; J Albrecht
Journal:  Hepatology       Date:  2000-11       Impact factor: 17.425

4.  Additive antiviral effects of lamivudine and alpha-interferon in chronic hepatitis B infection.

Authors:  D Mutimer; D Dowling; P Cane; D Ratcliffe; H Tang; K O'Donnell; J Shaw; E Elias; D Pillay
Journal:  Antivir Ther       Date:  2000-12

5.  Prevalence of hepatitis C among pregnant women attending an inner London obstetric department: uptake and acceptability of named antenatal testing.

Authors:  C Ward; G Tudor-Williams; T Cotzias; S Hargreaves; L Regan; G R Foster
Journal:  Gut       Date:  2000-08       Impact factor: 23.059

6.  Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.

Authors:  H Tanaka; H Tsukuma; A Kasahara; N Hayashi; H Yoshihara; M Masuzawa; T Kanda; T Kashiwagi; A Inoue; M Kato; A Oshima; Y Kinoshita; T Kamada
Journal:  Int J Cancer       Date:  2000-09-01       Impact factor: 7.396

7.  Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up.

Authors:  D Mutimer; G Dusheiko; C Barrett; L Grellier; M Ahmed; G Anschuetz; A Burroughs; S Hubscher; A P Dhillon; K Rolles; E Elias
Journal:  Transplantation       Date:  2000-09-15       Impact factor: 4.939

8.  Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine.

Authors:  C A Sponseller; B R Bacon; A M Di Bisceglie
Journal:  Liver Transpl       Date:  2000-11       Impact factor: 5.799

9.  Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group.

Authors:  R N Chien; Y F Liaw; M Atkins
Journal:  Hepatology       Date:  1999-09       Impact factor: 17.425

10.  Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.

Authors:  R Perrillo; E Schiff; E Yoshida; A Statler; K Hirsch; T Wright; K Gutfreund; P Lamy; A Murray
Journal:  Hepatology       Date:  2000-07       Impact factor: 17.425
View more
  5 in total

1.  Incidence and prevalence of hepatitis c virus infection among persons who inject drugs in New York City: 2006-2013.

Authors:  Ashly E Jordan; Don C Des Jarlais; Kamyar Arasteh; Courtney McKnight; Denis Nash; David C Perlman
Journal:  Drug Alcohol Depend       Date:  2015-04-13       Impact factor: 4.492

2.  Generation of cytotoxic T cell against HBcAg using retrovirally transduced dendritic cells.

Authors:  Chuan-Lin Ding; Kun Yao; Tian-Tai Zhang; Feng Zhou; Lin Xu; Jiang-Ying Xu
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

3.  Oxymatrine therapy for chronic hepatitis B: a randomized double-blind and placebo-controlled multi-center trial.

Authors:  Lun-Gen Lu; Min-De Zeng; Yi-Min Mao; Ji-Qiang Li; Mo-Bin Wan; Cheng-Zhong Li; Cheng-Wei Chen; Qing-Chun Fu; Ji-Yao Wang; Wei-Min She; Xiong Cai; Jun Ye; Xia-Qiu Zhou; Hui Wang; Shan-Ming Wu; Mei-Fang Tang; Jin-Shui Zhu; Wei-Xiong Chen; Hui-Quan Zhang
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

4.  Evaluation of adverse effects of mutein forms of recombinant human interferon alpha-2b in female swiss webster mice.

Authors:  H Rachmawati; A Merika; R A Ningrum; K Anggadiredja; D S Retnoningrum
Journal:  Biomed Res Int       Date:  2013-05-02       Impact factor: 3.411

5.  Does anybody read "evidence-based" articles?

Authors:  Yoon K Loke; Sheena Derry
Journal:  BMC Med Res Methodol       Date:  2003-07-31       Impact factor: 4.615
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.